Harvard Business Review

APRIL 16, 2012

This raises the question of whether retaining strategic cash makes economic sense and should be viewed as a legitimate corporate finance tool in today's environment. Strategic cash also can be used to finance long-term reinvestment programs in the business—which is especially valuable to companies in capital-intensive industries (e.g.,

Company 13

Company Cost of Capital Finance Long-term 13

Harvard Business Review

JULY 4, 2017

With that in mind, I can see three potential scenarios for how Apple might play in the autonomous car market. Some of them may never enter the car market, or may at least significantly delay a move toward ownership. Apple has a great intuitive feel for how consumers see a market, versus how manufacturers see it. Or a kitchen?

Transportation 8

Transportation Sports Pharmaceuticals Health Care 8

Harvard Business Review

OCTOBER 20, 2016

Meanwhile the Institute of International Finance forecasted net capital flows for emerging markets in 2015 would be negative for the first time since 1988. pharmaceutical company, had to abandon its $106 billion attempt to buy British drug maker AstraZeneca in the face of opposition from UK politicians.

Globalization 8

Globalization Banking Policies Politics 8

Harvard Business Review

AUGUST 2, 2011

In reality, each country needs the other to succeed in order to thrive — to finance growth, secure export markets, train talent, transfer technology, and more. For example, pharmaceutical firms license compounds to each other and co-promote products in different markets. Facilitate discussion between competitors.

Apparel 15

Apparel Pharmaceuticals Finance Licensing 15

Harvard Business Review

JUNE 16, 2016

In July 2015, Novartis launched its new heart failure drug, Entresto, which Forbes in 2014 predicted would be a blockbuster — with expected sales of $10 billion annually — as the potential market in the US exceeds 5 million people with a heart failure condition. The failure stemmed from resistance in the U.S.

Planning 8

Planning Competitive Intelligence Pharmaceuticals Brand 8

Harvard Business Review

NOVEMBER 9, 2011

COOs are relatively common in service industries such as financial services, energy, information technology and telecommunications, but in manufacturing sectors — such as automotive, chemical, and pharmaceutical companies — they are relatively rare. What do you think?

COO 12

COO Sample Telecommunications Automotive 12

Harvard Business Review

AUGUST 3, 2012

They might make a targeted acquisition here or there, form an alliance now and again, or license in some specialized technology, but by and large they made their own drugs, supporting big, fully staffed research labs, which they would then market themselves. As yet, the facts don't seem to substantiate the fears.

Licensing 13

Licensing Depreciation Pharmaceuticals Budgeting 13

Harvard Business Review

MAY 5, 2016

But peruse some of the recent headlines about Iran , and you might wonder whether the market’s potential was overstated. However, despite a weakened economy, political tensions, market uncertainty, and the lingering effects of sanctions, Iran remains an important opportunity for multinationals in emerging markets.

Tourism 8

Tourism Banking Due Diligence Hotels 8

Harvard Business Review

OCTOBER 13, 2011

Bank marketing materials focus on the dreams, anxieties and goals of consumers. The pharmaceutical industry also creates products with complex interactions and potentially dangerous side effects. Yet unlike in finance, where distributing risk across institutions is the goal, in drug development the focus is on isolating risk.

Banking 10

Banking Pharmaceuticals Microfinance Risk Management 10

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. It’s not just products.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

APRIL 5, 2012

If you spend much time around salespeople, it won't take long before you hear them griping about the issue that is the profession's biggest trouble spot: disagreement over the market potential of a group of accounts or a territory. In exit interviews, the people who leave imply they don't have enough market potential to succeed.".

Retail 9

Retail Incentives Tactics Pharmaceuticals 9

Harvard Business Review

AUGUST 6, 2015

I made a career switch seven years ago, when I went from working as a reporter at the Financial Times , where I covered health care in the United States, to consulting — advising CEOs in the pharmaceutical industry on thought leadership and articulating their corporate strategies. You should also ask: How you should market them?

Career 8

Career Skills Health Care Pharmaceuticals 8

Harvard Business Review

FEBRUARY 26, 2013

An "earn-your-way" strategy is sometimes necessary in markets with high uncertainty or when a company is cash-strapped. But when leaders take this conservative growth approach even when there is reasonable certainty of success and available financing, they undersize their sales forces and forfeit opportunity.

Company 8

Company Short-term Long-term Cost 8

Harvard Business Review

FEBRUARY 24, 2015

The first category is exogenous factors over which the business has little control: the growth of the markets into which it sells; the competitive intensity and thus the average profitability of the industry in which it operates; or the fragmentation of its industry and thus the scope for a growth-by-acquisition approach.

Chemicals 8

Chemicals How To Kahneman Reputation 8

Harvard Business Review

MARCH 24, 2011

Competitors whispered that Gupta was committing the most un-McKinsey-like of sins: cutting price to get into new markets. I couldn't believe some of the people I was seeing from McKinsey," recalls a partner at another strategy firm. Among McKinsey's biggest clients in the 1990s were pharmaceuticals and financial-services companies.

McKinsey 14

McKinsey Consultative Waterman Intellectual Capital 14

Harvard Business Review

JANUARY 26, 2011

Companies included in the ETF include major airlines, pharmaceuticals, industrials, and technology. By the end of October in 2010, the market value of the 100 constituent stocks reached 582 billion RMB, accounting for 31% of the total market value of the Shanghai Stock Exchange's A shares.

Long-term 14

Long-term Sample Report Pharmaceuticals 14

Harvard Business Review

FEBRUARY 4, 2013

Just under 1,000 companies account for half of the world's market capitalization, Eccles notes. Breakthrough requires an end to systemic inequities by opening up processes, information - and markets. Perhaps surprisingly, two leading examples come from pharmaceutical companies. Breakthrough Finance.

EPS 8

EPS Innovation CEO Pharmaceuticals 8

Harvard Business Review

SEPTEMBER 13, 2011

Here are some common examples: When pharmaceutical companies announce that a new drug has been "approved," they are actually saying that their researchers made some breakthrough discoveries as far back as fifteen years ago. Financial firms that report quarterly earnings are probably jumping the gun with their results.

Short-term 14

Short-term Pharmaceuticals Long-term Maturity 14

Harvard Business Review

SEPTEMBER 4, 2015

We’ve found that CEOs of big pharmaceutical companies, for example, are more likely to have a background as company lawyers, salespeople, or finance managers, than one in medicine or pharmaceutical R&D. Pharmaceuticals. The data captured a 20-year period, from 1995 to 2014. Overall, it is a messy picture.

CEO 8

CEO Innovation Pharmaceuticals Merchandising 8

Harvard Business Review

NOVEMBER 20, 2015

He is poised to become the leader in this segment of a multi-billion dollar market. Compliance is crucial for pharmaceutical makers such as Abbott and Amgen – a “ Form 483 ” warning from an FDA inspector can shut down a drug facility in an instant and even land top executives in jail.

Supply Chain 8

Supply Chain Collins Golden Handcuff Pharmaceuticals 8

Harvard Business Review

JANUARY 26, 2016

And yet for almost every company that uses CI in their decision-making, there’s another that disregards CI’s mix of industry analysis, rival positions, and market insight to their detriment. and European corporations, from CI-trained analysts in marketing, business development, strategy, R&D, finance, and other fields.

Competitive Intelligence 8

Competitive Intelligence Company CAPEX Analysis 8

Harvard Business Review

JUNE 20, 2017

The possibility of a contentious renegotiation of the North American Free Trade Agreement (NAFTA) has led to delayed or canceled investments in what has been one of Latin America’s most economically stable markets. Renegotiating NAFTA. Indeed, on May 18 the Trump administration notified the U.S.

Supply Chain 8

Supply Chain Depreciation Uncertainty Marketing 8